Medical device company Boston Scientific (NYSE: BSX) will be reporting earnings this Wednesday before market hours. Here’s what you need to know.
Boston Scientific beat analysts’ revenue expectations by 2% last quarter, reporting revenues of $4.66 billion, up 20.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ organic revenue estimates and a solid beat of analysts’ EPS estimates.
Is Boston Scientific a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Boston Scientific’s revenue to grow 18.8% year on year to $4.89 billion, improving from the 14.5% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Boston Scientific has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 3.1% on average.
Looking at Boston Scientific’s peers in the healthcare equipment and supplies segment, only Abbott Laboratories has reported results so far. It beat analysts’ revenue estimates by 0.9%, delivering year-on-year sales growth of 7.4%. The stock was down 6.1% on the results.
Read our full analysis of Abbott Laboratories’s earnings results here.Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.1% on average over the last month. Boston Scientific is up 1.5% during the same time.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
